- Home
- NXTC vs AMS Comparison
NXTC vs AMS Comparison
Compare NXTC & AMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- AMS
- Stock Information
- Founded
- NXTC 2015
- AMS 1980
- Country
- NXTC United States
- AMS United States
- Employees
- NXTC N/A
- AMS 44
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- AMS Medical Specialities
- Sector
- NXTC Health Care
- AMS Health Care
- Exchange
- NXTC Nasdaq
- AMS Nasdaq
- Market Cap
- NXTC 13.0M
- AMS 14.9M
- IPO Year
- NXTC 2019
- AMS N/A
- Fundamental
- Price
- NXTC $10.77
- AMS $2.38
- Analyst Decision
- NXTC Strong Buy
- AMS
- Analyst Count
- NXTC 2
- AMS 0
- Target Price
- NXTC $25.50
- AMS N/A
- AVG Volume (30 Days)
- NXTC 49.2K
- AMS 114.5K
- Earning Date
- NXTC 11-06-2025
- AMS 11-12-2025
- Dividend Yield
- NXTC N/A
- AMS N/A
- EPS Growth
- NXTC N/A
- AMS N/A
- EPS
- NXTC N/A
- AMS N/A
- Revenue
- NXTC N/A
- AMS $29,251,000.00
- Revenue This Year
- NXTC N/A
- AMS $5.06
- Revenue Next Year
- NXTC N/A
- AMS N/A
- P/E Ratio
- NXTC N/A
- AMS N/A
- Revenue Growth
- NXTC N/A
- AMS 26.61
- 52 Week Low
- NXTC $2.69
- AMS $2.22
- 52 Week High
- NXTC $19.20
- AMS $3.59
- Technical
- Relative Strength Index (RSI)
- NXTC 77.64
- AMS 46.96
- Support Level
- NXTC $6.23
- AMS $2.22
- Resistance Level
- NXTC $13.17
- AMS $2.35
- Average True Range (ATR)
- NXTC 0.91
- AMS 0.13
- MACD
- NXTC 0.50
- AMS -0.02
- Stochastic Oscillator
- NXTC 67.51
- AMS 17.98
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.